With the ever changing evolution of the gig economy, many industries have had to adjust to meet the demands of the market to continue to ensure that they were still hiring top talents, that goes for industries like Pharma and Biotech. As outlined in this Pharma Exec article published this year, Pharma has been considered the employer of choice for a long time, an industry where many employees would jumpstart their careers as they sought the opportunity to grow within a company or move comfortably to another industry employer. 

We’re excited to announce the launch of Clora’s employer referral program.

Here at Clora, we believe that everything is better when worked on as a team. Especially when it comes to publishing a project or hiring the right consultant. That’s why we’re excited to release our latest sets of features, Project and Proposal Feedback.

We’re excited to be launching our latest feature Open Opportunities to help consultants find rewarding projects that matches their skillsets and preferences. Through the Open Opportunities marketplace, Clora is thrilled to connect you with top-tier employers and high quality projects. Simply log into your consultant account to browse all open projects. 

• A former director of clinical operations was matched to a pioneering combination product company working on trauma patients to drive their pivotal trials forward.
• A translational pharmacologist and leading scientist in the immuno-oncology arena was matched to a small biotech company focused on novel T-Cell based treatments to initiate collaborations to source tumor tissue.
• A former BMS program manager was matched to a publicly traded rare disease company to drive development plans forward across regulatory, CMC, and clinical activities.
• A seasoned former Gilead biostatistician with over three decades of IND-enabling experience was matched with an early-stage biotech company focused on preclinical development for neurological indications.
• A seasoned R&D Executive and one of Clora’s top-tier consultants in clinical development was matched as an interim CMO with a biotech company focused on predictive medicine for hematological indications.
• A senior IT professional with experience in the management of IT implementation/compliance in Pharma R&D matched to a gene therapy company to implement Laboratory Information Management Systems (LIMS).

Staff shortages have escalated in the last three months to become the top emerging risk that organizations face globally, according to Gartner, Inc.’s latest Emerging Risks Survey.

The survey of 137 senior executives in 4Q18 showed that concerns about “talent shortages” now outweigh those around “accelerating privacy regulation” and “cloud computing”, which were the top two risks in the 3^rd Quarter 2018  Emerging Risk Monitor.

From Uber to Google to Facebook, the two-sided marketplace is a business model that creates value by facilitating exchanges between two or more interdependent groups, usually consumers and producers. In the case of Clora’s work within the life science sector, the two specific groups are employers and consultants.

Today, more and more life science companies are accelerating their development timelines through the use of a leaner, faster-paced approach to talent recruitment and team-building. This model is made possible by both advances in recruiting technology and the influx of many highly skilled consultants who have actively chosen to make consulting work their "full time" job.

PALO ALTO, Calif. & BOSTON--Science Exchange, the world’s leading marketplace for outsourced R&D™, today announced a strategic partnership with Clora, a technology platform that precisely matches life science companies with flexible, uniquely-qualified expertise.

This venture-backed, clinical stage company is developing novel delivery approaches to cell therapy. Their lead product is being developed to treat Acute Kidney Injury (AKI), the sudden loss of kidney function that can occur following cardiac surgery.

Clora has worked on 3 projects with this company relating to the filing of their IND and the execution of their early stage clinical programs.